NIMHD SBIR/STTR Program

NIMHD SBIR/STTR Commercialization Readiness Pilot

Funds NIH-funded small businesses moving SBIR or STTR projects from late-stage development to commercialization.

The NIMHD SBIR/STTR Commercialization Readiness Pilot is the institute-relevant route into NIH PAR-27-098, the parent SB1 CRP opportunity. Simpler.Grants.gov lists the opportunity as posted May 28, 2026, and closing April 5, 2029.

CRP is a later-stage commercialization route, not a base feasibility grant. The source says the program helps small business concerns move NIH-funded SBIR or STTR projects from late-stage development to commercialization. It also says CRP supports work that Phase II and Phase IIB awards do not typically support, including independent replication, IND- or IDE-enabling studies, clinical studies, manufacturing scale-up and related quality activities, and regulatory or other specialized technical support.

Eligibility is direct to United States small business concerns, even though the general eligible-applicant list includes broader categories. The additional eligibility text controls the applicant path: only United States small business concerns are eligible to submit applications for this opportunity.

Applications follow NIH standard receipt dates. NIH SEED lists standard application due dates of September 5, January 5, and April 5, with weekend or federal-holiday dates moved to the next business day. The opportunity closes April 5, 2029.

The main practical issue is maturity. CRP is for NIH-funded SBIR/STTR projects already moving toward commercialization, so a company without NIH small-business project history should start with SBIR or STTR, while a company bridging Phase II to commercialization may compare CRP with Phase IIB Strategic Breakthrough.